Article

GALILEO: Aflibercept provides marked improvement in visual acuity in results from follow-up to 76 weeks

Intravitreal injection of aflibercept provides marked improvement in visual acuity in treatment-naive eyes with macular edema secondary to central retinal vein occlusion in results from follow-up to 76 weeks in the phase III GALILEO study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
Related Content
NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
July 25th 2025

NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
July 24th 2025

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Scuba divers and surfers face dual light exposure that may accelerate AMD
July 24th 2025

Scuba divers and surfers face dual light exposure that may accelerate AMD

(Image credit: AdobeStock/iQoncept) Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
July 23rd 2025

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence

© 2025 MJH Life Sciences

All rights reserved.